Structure of Zerumbone
CAS No.: 471-05-6
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Zerumbone, a monocyclic sesquiterpene compound isolated from the rhizomes of Zingiber zerumbet Smith, potently inhibits the activation of Epstein-Barr virus with an IC50 of 0.14 mM. Zerumbone has anti-cancer, antioxidant, anti-inflammatory and anti-proliferative activity[1][2].
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 471-05-6 |
Formula : | C15H22O |
M.W : | 218.33 |
SMILES Code : | CC(/C=C/1)(C)C/C=C(C)/CC/C=C(C)/C1=O |
MDL No. : | MFCD03700769 |
GHS Pictogram: |
![]() ![]() ![]() |
Signal Word: | Danger |
Hazard Statements: | H302-H319-H372-H410 |
Precautionary Statements: | P273-P301+P312+P330-P305+P351+P338-P314 |
Class: | 9 |
UN#: | 3077 |
Packing Group: | Ⅲ |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
Huh7 | 50 µM | 24 and 48 hours | Induced cell cycle arrest and apoptosis | Mol Cancer Res. 2018 Feb;16(2):256-268 |
MHCC-LM3 | 50 µM | 24 hours | Inhibited PI3K/AKT/mTOR and STAT3 signaling pathways | Mol Cancer Res. 2018 Feb;16(2):256-268 |
Murine bone marrow-derived macrophages | 10-50 µM | 1 hour pretreatment followed by LPS or LPS/ATP treatment | Suppressed the production of IL-6, TNF-α, and IL-1β | Front Pharmacol. 2021 May 11;12:652860 |
J774A.1 cells | 20 and 40 µM | 1 hour pretreatment followed by LPS treatment for 2 hours | Inhibited the phosphorylation of ERK, did not affect the phosphorylation of JNK and p38 MAPK | Front Pharmacol. 2021 May 11;12:652860 |
Murine peritoneal macrophages | 10-50 µM | 1 hour pretreatment followed by LPS treatment for 24 hours | Inhibited the production of NO and IL-6, varied effects on TNF-α depending on concentration | Front Pharmacol. 2021 May 11;12:652860 |
J774A.1 cells | 10-50 µM | 1 hour pretreatment followed by LPS treatment for 24 hours | Suppressed the production of IL-6, increased TNF-α production at high doses | Front Pharmacol. 2021 May 11;12:652860 |
J774A.1 cells | 10-50 µM | 1 hour pretreatment followed by LPS treatment for 24 hours | Inhibited the production of NO, IL-6, and PGE2, suppressed the expression of iNOS and COX-2 | Front Pharmacol. 2021 May 11;12:652860 |
J774A.1 cells | 0-50 µM | 1 hour pretreatment followed by LPS/ATP or LPS/nigericin treatment | Suppressed the secretion of IL-1β, inhibited the activation of NLRP3 inflammasome | Front Pharmacol. 2021 May 11;12:652860 |
Human neuroblastoma SH-SY5Y cells | 1 µM | 24 hours | To investigate the effect of MSC on apoptosis in Clu-knockdown SH-SY5Y cells. Results showed that 1 μM MSC could reverse the decrease in antioxidative capacity, Bcl-2/Bax ratio, and increase in caspase-8 activity caused by Clu-knockdown, thereby inhibiting apoptosis and maintaining cell viability. | Invest New Drugs. 2022 Apr;40(2):224-231 |
Mouse neuroblastoma N2a cells | 1 µM | 24 hours | To investigate the effect of MSC on apoptosis in Clu-knockdown N2a cells. Results showed that 1 μM MSC could reverse the decrease in antioxidative capacity, Bcl-2/Bax ratio, and increase in caspase-8 activity caused by Clu-knockdown, thereby inhibiting apoptosis and maintaining cell viability. | Invest New Drugs. 2022 Apr;40(2):224-231 |
Primary microglial cells | 1, 3, or 10 μg/ml | 24 hours | Zerumbone significantly reduced the production of IL-1β and TNF-α while increasing IL-10 production, and dose-dependently increased the mRNA levels of CD206, IL-10, and ARG-1, demonstrating its anti-inflammatory effects and ability to promote an anti-inflammatory phenotype in primary microglial cells. | J Neuroinflammation. 2020 Feb 17;17(1):61 |
N9 microglial cell line | 1, 3, or 10 μg/ml | 24 hours | Zerumbone significantly suppressed NO production and dose-dependently decreased the mRNA levels of IL-1β, IL-6, iNOS, and TNF-α, while increasing the mRNA levels of CD206, IL-10, and ARG-1, indicating its anti-inflammatory effects and ability to promote a switch in microglial phenotype from pro-inflammatory to anti-inflammatory. | J Neuroinflammation. 2020 Feb 17;17(1):61 |
U87MG cells | 10-50 µM | 24 hours | Zerumbone decreased the viability of U87MG cells in a dose-dependent manner. | J Biomed Sci. 2012 Oct 5;19(1):86 |
GBM8401 cells | 10-50 µM | 24 hours | Zerumbone induced apoptosis in GBM8401 cells in a dose-dependent manner, confirmed by MTT assay and flow cytometry. | J Biomed Sci. 2012 Oct 5;19(1):86 |
SH-SY5Y neuroblastoma cells | 8 mg/ml | 24 hours | To investigate the effect of Zerumbone on the expression of α2A-adrenergic, TRPV1, and NMDA NR2B receptors in LPS-induced SH-SY5Y neuroblastoma cells. Results showed that Zerumbone significantly increased the expression of α2A-adrenergic receptors while down-regulating TRPV1 and NMDA NR2B receptors. | Front Pharmacol. 2020 Mar 4;11:92 |
HCT116 colon cancer cells | 5, 10, 20 µM | 24 hours | To investigate the inhibitory effect of Zerumbone on the proliferation of HCT116 cells and its association with TNF-α. Results showed that with increasing concentration of Zerumbone, there was a reduction in HCT116 cell proliferation and higher TNF-α inhibition. | Sci Rep. 2018 Mar 6;8(1):4090 |
L929 cells | 30.5 ± 1.5 µM (IC50) | 24 hours | To assess the toxicity of Zerumbone on normal L929 cells, results showed lower toxicity in normal cells. | Cell Prolif. 2019 Mar;52(2):e12558 |
HeLa cells | 14.2 ± 0.5 µM (IC50) | 24 hours | To evaluate the inhibitory effect of Zerumbone on HeLa cell proliferation, results showed selective inhibition through enhanced cellular uptake. | Cell Prolif. 2019 Mar;52(2):e12558 |
FaDu cells | 10, 30, 100 µM | 24 hours (apoptosis assay), 48 hours (qPCR, Western blot, ELISA analyses), 14 days (plate clone formation assay) | Tilianin inhibited FaDu cell proliferation and induced apoptosis in a dose-dependent manner. It upregulated pro-apoptotic factors Bax and Bad, downregulated anti-apoptotic factors Bcl-2 and Bcl-xL, activated caspase-3 and PARP, and stimulated cytochrome c release, thereby inducing apoptosis via the mitochondrion-dependent intrinsic apoptotic pathway. | Nutrients. 2022 Dec 19;14(24):5402 |
Helicobacter pylori 60190 | 6.25, 12.5, 25, 50, 100 µM | 3 days | Determine the minimal inhibitory concentration (MIC) of Zerumbone, which was 50 µM in agar dilution and 100 µM in broth dilution | Molecules. 2021 May 1;26(9):2663 |
HT29/C1 cells | 6.25 µM | 3 hours | Suppressed BFT-induced NF-κB signaling and IL-8 secretion but did not affect E-cadherin cleavage. | Int J Mol Sci. 2019 Sep 14;20(18):4560 |
Candida albicans (CaR) | 128 µg/mL | 5, 10, 20 min | To assess the effect of Zerumbone on fluconazole-resistant Candida albicans biofilms. Results showed that ZER at 128 µg/mL reduced cellular viability by approximately 36.99% and decreased insoluble biomass (13%), proteins (18%), water-soluble polysaccharides (65%), alkali-soluble polysaccharides (10%), and extracellular DNA (23%) in CaR biofilms. | J Fungi (Basel). 2023 May 16;9(5):576 |
Candida albicans (CaS) | 256 µg/mL | 5, 10, 20 min | To assess the effect of Zerumbone on fluconazole-susceptible Candida albicans biofilms. Results showed that ZER at 256 µg/mL reduced cellular viability by approximately 38.51% and decreased total biomass (57%), insoluble biomass (45%), water-soluble polysaccharides (65%), proteins (18%), and extracellular DNA (78%) in CaS biofilms. | J Fungi (Basel). 2023 May 16;9(5):576 |
RAW 264.7 cells | 2.5~20 µM | 6 hours | Zerumbone inhibited iNOS and COX-2 protein expressions and reduced NO and PGE2 production, while inducing HO-1 expression. | Int J Mol Sci. 2016 Feb 18;17(2):249 |
HepG2 | 14 µM | 72 hours | Inhibited HCC cell proliferation by G2/M phase arrest and inducing apoptosis | Mol Cancer Res. 2018 Feb;16(2):256-268 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
ICR mice | Chronic constriction injury (CCI)-induced neuropathic pain model | Intraperitoneal injection | 10 mg/kg | Single administration, behavioral tests conducted 30 minutes after administration | To investigate the anti-allodynic and antihyperalgesic effects of Zerumbone in the CCI-induced neuropathic pain model and its mechanisms. Results showed that Zerumbone exerted anti-neuropathic effects by modulating α1-, α2-, β1-, and β2-adrenoceptors as well as TRPV1 and NMDA NR2B receptors. | Front Pharmacol. 2020 Mar 4;11:92 |
ICR mice | Chronic constriction injury (CCI)-induced neuropathic pain model | Intraperitoneal injection | 10 mg/kg | Single administration, behavioral tests conducted 30 minutes post-administration | To elucidate the mechanisms underlying zerumbone’s antineuropathic actions via cannabinoid and PPAR receptors. Results showed that zerumbone exerts anti-allodynic and antihyperalgesic effects against mechanical allodynia and thermal hyperalgesia through CB1, PPARα, and PPARγ receptors. | Molecules. 2021 Jun 24;26(13):3849 |
Male ICR mice | Chronic constriction injury (CCI)-induced neuropathic pain model | Intraperitoneal injection | 10 mg/kg | Single administration, tests performed 30 minutes post-administration | To investigate the analgesic effects of Zerumbone via potassium channels and opioid receptors in CCI-induced neuropathic pain. Results showed that Zerumbone significantly alleviated mechanical allodynia and thermal hyperalgesia. | Molecules. 2020 Aug 26;25(17):3880 |
ICR mice | Acetic acid-induced writhing response model | Intraperitoneal injection | 10 or 50 mg/kg | Single dose | Zerumbone significantly reduced the number of acetic acid-induced writhing responses. | Int J Mol Sci. 2016 Feb 18;17(2):249 |
Male albino mice | ZEA-induced hepatotoxicity model | Oral gavage | 15 mg/kg | Once daily for 4 weeks | ZER exhibited a protective effect against ZEA-induced toxicity by ameliorating inflammation and oxidative stress-induced apoptosis. ZER decreased the levels of alkaline phosphatase and alanine aminotransferase (ALT) in serum and attenuated the inflammatory response by significantly reducing the levels of pro-inflammatory factors, including IL-1β, IL-6, and TNF-α. Additionally, ZER reduced the hepatic malondialdehyde (MDA) concentration and increased the activities of superoxide dismutase (SOD), glutathione (GSH), and catalase (CAT). ZER also alleviated ZEA-induced apoptosis by regulating the PI3K/AKT pathway and the expression of Nrf2 and HO-1. | Antioxidants (Basel). 2021 Oct 12;10(10):1593 |
NSG mice | Subcutaneous and orthotopic HCC xenograft models | Intraperitoneal injection | 20 mg/kg/day | Once daily for 3 weeks | Suppressed HCC xenograft growth and lung metastasis | Mol Cancer Res. 2018 Feb;16(2):256-268 |
APP/PS1 transgenic mice | Alzheimer's disease model | Oral gavage | 25 mg/kg | Once daily for 20 days | Zerumbone significantly ameliorated deficits in both non-cognitive and cognitive behaviors in transgenic APP/PS1 mice, reduced β-amyloid deposition, attenuated pro-inflammatory microglial activation in the cortex and hippocampus, and increased the proportion of anti-inflammatory microglia. Additionally, zerumbone downregulated the expression of key MAPK pathway molecules such as p38 and ERK. | J Neuroinflammation. 2020 Feb 17;17(1):61 |
Wistar albino rats | Collagen-induced arthritis (CIA) model | Oral | 25 mg/kg and 50 mg/kg | Once daily for 20 days | To evaluate the therapeutic effects of Zerumbone on collagen-induced arthritis. Results showed that Zerumbone significantly reduced the clinical severity of arthritis, decreased oxidative stress and inflammatory cytokine levels, and restored normal histology in joints and tissues. | ACS Omega. 2023 Jan 10;8(3):2982-2991 |
C57BL/6 mice | ETBF infection-induced colitis model | Oral | 30 or 60 mg/kg | Once daily for 7 days | Zerumbone reduced ETBF-induced colonic inflammation, prevented weight loss and splenomegaly, reduced colonic inflammation with decreased macrophage infiltration, and decreased expression of IL-17A, TNF-α, KC, and iNOS, while inhibiting NF-κB signaling. | Int J Mol Sci. 2019 Sep 14;20(18):4560 |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
4.58mL 0.92mL 0.46mL |
22.90mL 4.58mL 2.29mL |
45.80mL 9.16mL 4.58mL |
Tags: Zerumbone | EBV | Caspase | Apoptosis | Bacterial | Epstein-Barr Virus | Coav-3 paw edema | granuloma | anti-cancer | anti-bacterial | anti-inflammatory | anti-proliferative | anti-mutagenic | inhibitor | 471-05-6 |
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL